Product Information

AUSTEDO XR TITR(12-18-24-30 MG) is a brand product labeled by Teva Neuroscience, Inc., priced at $249.3230 per EA under NDC 68546047729. Its NADAC has been published 32 times since Nov 19, 2025.

AUSTEDO XR TITR(12-18-24-30 MG)

deutetrabenazine
$249.3230per EA

NDC

68546047729

Classification

Brand

Dosage Form

KIT

Last Updated

1/1/2026

Approval Type

New Drug (NDA)

FDA Application

NDA216354

On Market Since

7/1/2024

Price Statistics

The NADAC for AUSTEDO XR TITR(12-18-24-30 MG) has been published 32 times since Nov 19, 2025, and over the history we have for it it has risen 5.5%. The table below summarizes its recorded NADAC range and movement.

Current price$249.3230 per EA
All-time high$249.3230 (Jun 24, 2026)
All-time low$236.3251 (Dec 17, 2025)
52-week high$249.3230
52-week low$236.3251
Median price$249.3230
Average price$246.4905
Largest weekly change+5.5% (Jan 7, 2026)
Weeks tracked32
Tracking sinceNov 19, 2025

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+5.5%

1Y

N/A

3Y

N/A

5Y

N/A

All

+5.5%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the deutetrabenazine market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Frequently asked questions

What is the NADAC price of AUSTEDO XR TITR(12-18-24-30 MG)?

The current National Average Drug Acquisition Cost (NADAC) for AUSTEDO XR TITR(12-18-24-30 MG), manufactured by Teva Neuroscience, Inc., is $249.3230 per EA (NDC 68546047729), effective Jun 24, 2026.

How has the price of AUSTEDO XR TITR(12-18-24-30 MG) changed over time?

Over the history we have for it, the NADAC for AUSTEDO XR TITR(12-18-24-30 MG) has risen 5.5%. It has been tracked across 32 weekly CMS publications since Nov 19, 2025.

What are the highest and lowest recorded NADAC prices for AUSTEDO XR TITR(12-18-24-30 MG)?

Since Nov 19, 2025, the NADAC for AUSTEDO XR TITR(12-18-24-30 MG) has ranged from a low of $236.3251 (Dec 17, 2025) to a high of $249.3230 (Jun 24, 2026), with a median of $249.3230 per EA.

Are there cheaper alternatives to AUSTEDO XR TITR(12-18-24-30 MG)?

No other NADAC-published product currently shares the active ingredient, strength, and dosage form of AUSTEDO XR TITR(12-18-24-30 MG), so no direct lower-cost alternative is listed.

Who manufactures AUSTEDO XR TITR(12-18-24-30 MG)?

AUSTEDO XR TITR(12-18-24-30 MG) (NDC 68546047729) is labeled by Teva Neuroscience, Inc., and CMS classifies it as a brand product.

Related Drugs

Same classification

No related drugs found.